Abstract 434P
Background
A number of provincial online treatment guidelines/protocols exist in Canada, which differ in the information contained and the ease of use. Currently there is no national evidence-based, consensus-driven cancer treatment protocol for use at the point of care. The aim of such a resource would be to support Medical Oncologists (MOs) in the delivery of cancer treatment at the clinic interface and potentially improve patient outcomes by reducing treatment variation across Canada.
Methods
The study was conducted in two stages. Available provincial cancer treatment protocols were evaluated with regards to: content for chemotherapy, immunotherapy, ease of use, toxicity, dosing recommendations, reference studies. Canadian MOs were invited to participate in an anonymous survey distributed through the Canadian Association of Medical Oncologists. The assessment included: current online resources (OR) used, information provided, ease of use, relevance to point of care use, need for a national Canadian resource. MOs were asked to review a comparator Pan-Australian OR.
Results
40/327 responded: 28% BC, 26% ON and the rest from other provinces. 82%, 54% and 23% respectively used the BC and ON and other provincial ORs. 50% used ≥2 websites. 62% found the website of choice easy to use, 33% felt it had updated immune therapy information and 26% felt it was updated regularly. The OR used met the MO need for dose/scheduling in 87.5% cases but only 50% and 37.5% cases for AEs and reference information respectively. Criteria evaluated in the ORs included: dosing, toxicity modification, AEs, monitoring, references and other criteria. 95% of MOs felt that a single portal aimed at point of care for Canadian MOs would be of value. 64% felt that the international comparator was better than the current OR being used.
Conclusions
There is variation in the current Canadian OR used by MOs in Canada with a need for national evidence-based, cancer treatment protocols/information for use at the point of care. To develop such a Pan-Canadian website resource, further analysis and infrastructure is required. Such a resource would potentially reduce treatment variability and augment quality of care delivered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session
424P - Hippocampus sparing in volumetric modulated arc therapy (VMAT) for brain tumour radiotherapy treatment
Presenter: Eva Yi Wah Cheung
Session: e-Poster Display Session
425P - The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents
Presenter: Chun Loo Gan
Session: e-Poster Display Session
426P - A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Presenter: Marcia S. Brose
Session: e-Poster Display Session
427P - On the clinical implications of systemic and local immune responses in human angiosarcoma
Presenter: Jason Yongsheng Chan
Session: e-Poster Display Session
428P - Prognostic value of clinico-pathological characteristics and peripheral monocyte counts in localised extra-meningeal solitary fibrous tumours treated with surgical resection
Presenter: Ryan Lim
Session: e-Poster Display Session
429P - Demographics, pattern of care, and outcome analysis of malignant melanoma cases from a tertiary care centre in India
Presenter: Anshul Agarwal
Session: e-Poster Display Session
430P - Teenagers and young adult cancers in rural central India: Access to age-appropriate care
Presenter: Runu Sharma
Session: e-Poster Display Session
431P - Quantitative study of two critical lncRNAs in patients with glioma tumours
Presenter: Kamal Mohammadian
Session: e-Poster Display Session
432P - Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma
Presenter: Mustafa Gürbüz
Session: e-Poster Display Session